Cornercap Investment Counsel’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $2.41M | Sell |
10,529
-144
| -1% | -$32.8K | 1.19% | 10 |
|
|
2025
Q3 | $2.47M | Sell |
10,673
-180
| -2% | -$36.7K | 1.23% | 6 |
|
|
2025
Q2 | $2.01M | Buy |
10,853
+1,933
| +22% | +$359K | 1.05% | 11 |
|
|
2025
Q1 | $1.87M | Sell |
8,920
-108
| -1% | -$21K | 0.98% | 16 |
|
|
2024
Q4 | $1.6M | Buy |
+9,028
| New | +$1.66M | 0.52% | 34 |
|
|
2023
Q2 | – | Sell |
-18,426
| Closed | -$2.94M | – | 566 |
|
|
2023
Q1 | $2.94M | Buy |
18,426
+282
| +2% | +$43.1K | 0.52% | 25 |
|
|
2022
Q4 | $2.93M | Buy |
18,144
+632
| +4% | +$96.9K | 0.51% | 22 |
|
|
2022
Q3 | $2.35M | Sell |
17,512
-179
| -1% | -$25.7K | 0.44% | 37 |
|
|
2022
Q2 | $2.71M | Buy |
17,691
+725
| +4% | +$111K | 0.47% | 33 |
|
|
2022
Q1 | $2.75M | Sell |
16,966
-1,433
| -8% | -$208K | 0.31% | 64 |
|
|
2021
Q4 | $2.49M | Buy |
18,399
+1,782
| +11% | +$210K | 0.36% | 63 |
|
|
2021
Q3 | $1.79M | Buy |
+16,617
| New | +$1.9M | 0.2% | 122 |
|
|
2021
Q1 | – | Sell |
-37,910
| Closed | -$3.36M | – | 520 |
|
|
2020
Q4 | $3.36M | Buy |
+37,910
| New | +$3.64M | 0.48% | 58 |
|
|
2020
Q3 | – | Sell |
-3,200
| Closed | -$315K | – | 483 |
|
|
2020
Q2 | $315K | Buy |
+3,200
| New | +$282K | 0.05% | 394 |
|
|
2020
Q1 | – | Sell |
-43,035
| Closed | -$3.81M | – | 388 |
|
|
2019
Q4 | $3.81M | Sell |
43,035
-2,546
| -6% | -$211K | 0.51% | 55 |
|
|
2019
Q3 | $3.45M | Buy |
45,581
+40
| +0.1% | +$2.74K | 0.49% | 66 |
|
|
2019
Q2 | $3.31M | Buy |
45,541
+7,386
| +19% | +$581K | 0.44% | 73 |
|
|
2019
Q1 | $3.08M | Buy |
38,155
+16,045
| +73% | +$1.31M | 0.43% | 83 |
|
|
2018
Q4 | $2.04M | Buy |
22,110
+3,555
| +19% | +$313K | 0.32% | 101 |
|
|
2018
Q3 | $1.75M | Buy |
+18,555
| New | +$1.76M | 0.23% | 134 |
|
|
2018
Q1 | – | Sell |
-17,333
| Closed | -$1.68M | – | 397 |
|
|
2017
Q4 | $1.68M | Sell |
17,333
-1,888
| -10% | -$178K | 0.23% | 126 |
|
|
2017
Q3 | $1.71M | Sell |
19,221
-36,159
| -65% | -$2.75M | 0.24% | 121 |
|
|
2017
Q2 | $4.02M | Buy |
55,380
+9,125
| +20% | +$613K | 0.67% | 57 |
|
|
2017
Q1 | $3.01M | Buy |
46,255
+14,025
| +44% | +$882K | 0.51% | 70 |
|
|
2016
Q4 | $2.02M | Buy |
32,230
+17,435
| +118% | +$1.06M | 0.35% | 84 |
|
|
2016
Q3 | $933K | Buy |
14,795
+3,955
| +36% | +$256K | 0.17% | 137 |
|
|
2016
Q2 | $671K | Buy |
10,840
+935
| +9% | +$57K | 0.13% | 138 |
|
|
2016
Q1 | $565K | Buy |
+9,905
| New | +$552K | 0.11% | 153 |
|
Other funds holding ABBV
Cornercap Investment Counsel's ABBV Position: Q4 2025 in Review
Cornercap Investment Counsel reduced its AbbVie (ABBV) stake by 1.3% in Q4 2025, selling an estimated $32.8K and leaving 10,529 shares worth $2.41M. The position accounts for 1.19% of the portfolio, ranked #10.
Cornercap Investment Counsel first reported a position in ABBV in Q1 2016 and has held it in 28 quarters since. The position peaked at $4.02M in Q2 2017. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.
- Cornercap Investment Counsel held 10,529 shares of AbbVie worth $2.41M as of Q4 2025.
- Cornercap Investment Counsel sold 144 AbbVie shares in Q4 2025, an estimated $32.8K.
- AbbVie made up 1.19% of Cornercap Investment Counsel's portfolio in Q4 2025, its #10 holding.
- Cornercap Investment Counsel first reported a position in AbbVie in Q1 2016 and has held it in 28 quarters since.
- Cornercap Investment Counsel's AbbVie position peaked at $4.02M in Q2 2017.
- 4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.
Based on Cornercap Investment Counsel's 13F filing for Q4 2025, filed 13 Feb 2026.